EYA3 Inhibitors
EYA3 inhibitors belong to a distinctive chemical class that specifically targets the EYA3 protein, a member of the Eyes Absent (EYA) family of transcriptional coactivators. The EYA proteins play a crucial role in cellular development and homeostasis by acting as both phosphatases and transcriptional activators. Among the four members of the EYA family, EYA3 stands out for its involvement in various cellular processes, including DNA repair, cell proliferation, and differentiation.
As a phosphatase, EYA3 dephosphorylates key substrates, modulating their activity and influencing downstream signaling cascades.EYA3 function by selectively binding to its active site, impeding its phosphatase activity and disrupting its interactions with specific transcriptional partners. This interference with EYA3's dual functionality may lead to downstream effects on gene expression and signaling pathways, providing researchers with a valuable tool to elucidate the precise molecular mechanisms underlying various cellular processes. These inhibitors are designed with a high degree of specificity to minimize off-target effects and enhance their utility as research probes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verteporfin | 129497-78-5 | sc-475698 sc-475698A | 10 mg 100 mg | $347.00 $2710.00 | 5 | |
Verteporfin is an inhibitor of the Hippo/YAP signaling pathway, which EYA3 is known to interact with. It disrupts the YAP-TEAD interaction. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits EGFR, a receptor that can activate the same pathways as EYA3. It blocks the ATP binding site of EGFR. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits Src family kinases, which can activate the pathways that EYA3 is involved in. It blocks the ATP binding site of these kinases. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits HER2 and EGFR, receptors that can activate the same pathways as EYA3. It blocks the ATP binding site of these receptors. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits RAF kinases, which can activate the same pathways as EYA3. It blocks the ATP binding site of these kinases. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Sunitinib inhibits receptor tyrosine kinases, which can indirectly affect EYA3's activity. It blocks the ATP binding site of these kinases. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which can activate the same pathways as EYA3. It blocks the ATP binding site of PI3K. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which can activate the same pathways as EYA3. It blocks the activation of MEK. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits PI3K, which can activate the same pathways as EYA3. It forms a covalent bond with a key residue in PI3K. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB202190 inhibits p38 MAPK, which can activate the same pathways as EYA3. It blocks the ATP binding site of p38 MAPK. | ||||||